Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

NCT04926181 is registered in ClinicalTrials.gov with Rahul Aggarwal as lead sponsor.

NCT NCT04926181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04926181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
Lead sponsor
Rahul Aggarwal
Phase
Phase 2
Overall status
Terminated
Start date
March 16, 2022
Completion date
March 31, 2024
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, small cell carcinoma, small cell neuroendocrine carcinoma